Get started
Author

Yaopeng Wang

Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023 · Yifan Liu, Hongying Wang, et al. · Cancer Research · 18
IGSF9 promotes tumor invasion and metastasis through GSK-3β/β-catenin mediated EMT in lung cancer
2024 · Huiwen Luan, Ting Wang, et al. · Neoplasia · 16
Hypoxia-related gene DDIT4 as a therapeutic biomarker promotes epithelial-mesenchymal transition in lung adenocarcinoma via the MAPK/ERK signaling pathway
2025 · Xiaoyang Hua, Yaopeng Wang, et al. · International Immunopharmacology · 8
IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia
2025 · Lijun Hui, Jing Xiao, et al. · Blood Advances · 5
PDF
Tumor-associated macrophages educated by IGSF9 exhibit a senescence-associated secretory phenotype to promote tumor immune escape
2026 · Jiasheng Zhang, Xianhui Meng, et al. · Journal for ImmunoTherapy of Cancer · 3
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023 · Yifan Liu, Hongying Wang, et al. · 1
Combined detection of plasma HSP90α with conventional tumor markers improves postoperative recurrence detection and predicts survival in advanced gastric cancer: a retrospective cohort study
2026 · Ying Wang, Yaopeng Wang, et al. · Research Square
PDF
Figure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S8 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S6 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S7 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S3 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S4 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S5 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S2 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S1 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Works count: 51
Citation count: 51
H-index: 4
I10-index: 2
Year
Topic
Type